Oncology Overview: Sacituzumab Govitecan-hziy (Trodelvy) for Triple-Negative Breast Cancer
October 27th 2021Sacituzumab govitecan-hziy (Trodelvy) is indicated for the treatment of patients with triple-negative breast cancer who have received 2 prior therapies at minimum for metastatic disease.
Read More